摘要
目的比较培美曲塞联合顺铂方案(PP方案)与吉西他滨联合顺铂方案(GP方案)治疗晚期非小细胞肺癌的疗效及不良反应。方法检索Pubmed、Medline、Embase、Cochrane协作网、维普、万方、CNKI等中外数据库中PP方案和GP方案治疗晚期非小细胞肺癌的相关文献,应用Revman5.2进行数据处理。结果 Meta分析结果显示GP方案和PP方案在治疗晚期非小细胞肺癌的近期疗效和1年生存率方面的差异无统计学意义,在副作用方面,PP方案的血液毒性要小于GP方案。结论 GP方案和PP方案治疗晚期非小细胞肺癌的疗效相近,但PP方案的副作用较GP方案小。
Objective To compare the efficacy and toxic reactions of pemetrexed combined with cisplatin（PP） or gemcitabine combined with cisplatin（GP） in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods Articles about PP and GP in the treatment of NSCLC were selected from Pubmed,Medline,Embase,Cochrane,VIP,CBM,CNKI.Meta analysis was completed using Revman5.2.Results Meta analysis results showed that there were no significant difference in efficacy of PP and GP in the treatment of NSCLC and 1-year survival rate.In side effects,PP had less blood toxicity in GP.Conclusion PP and GP for NSCLC have similar effect,but PP has less side effects than GP.
出处
《实用癌症杂志》
2015年第11期1633-1638,共6页
The Practical Journal of Cancer
关键词
培美曲塞
吉西他滨
顺铂
非小细胞肺癌
META分析
Pemetrexed
Pemcitabine
Cisplatin
Non-small cell lung cancer（NSCLC）
Meta analysis
作者简介
通讯作者：陈小霞
